GlassScriptPhysician profile
Jennifer Tangeman
NPI 1689056806
$9,899.78
in general payments reported to CMS, 2019-2025
31 companies · $3,163 in 2025
The $3,163 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,964 · 2022: $2,209 · 2023: $2,231 · 2024: $332 · 2025: $3,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,726.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,833.96 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,060.23 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $937.79 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $849.86 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $834.38 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $501.93 | 2021-2025 | Trintellix |
| Corium, LLC | $482.59 | 2022-2025 | Azstarys |
| Lundbeck LLC | $401.11 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $350.81 | 2021-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $345.83 | 2022-2025 | Sunosi, Auvelity |
| Neurocrine Biosciences, INC. | $309.28 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $297.90 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $287.42 | 2021-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $246.95 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $167.89 | 2022-2025 | Qelbree, Qelbree |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $153.25 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $125.77 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $98.15 | 2021-2025 | Austedo Xr, Austedo |
| Adlon Therapeutics L.P. | $83.45 | 2021 | |
| Novo Nordisk INC | $78.81 | 2021-2025 | Wegovy |
| Eisai INC. | $62.88 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.66 | 2025 | Cobenfy |
| Noven Therapeutics, LLC | $56.33 | 2023-2025 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $45.63 | 2022 | |
| Merck Sharp & Dohme LLC | $45.34 | 2021 | |
| Indivior INC. | $44.37 | 2021-2023 | Sublocade |
| Tris Pharma INC | $43.15 | 2022-2023 | Dyanavel Xr |
| Avanir Pharmaceuticals, INC. | $33.70 | 2021 | |
| Almatica Pharma LLC | $30.93 | 2022-2025 | Loreev Xr |
| Neos Therapeutics, LP | $17.05 | 2025 | Adzenys Xr-Odt |
| Neuronetics, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Tangeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.